ARTIKEL REVIEW: PERKEMBANGAN DAN POTENSI VAKSIN DBD DARI BERBAGAI NEGARA

Monica Richelle Herdady, Resmi Mustarichie

Abstrak


Demam Berdarah Dengue (DBD) merupakan penyakit menular yang disebabkan virus dengue melalui Aedes aegyptidan Aedes albopictus. Infeksi virus dengue dapat menyebabkan Sindrom Syok Dengue yang dapat berujung pada kematian. Hingga saat ini, pengobatan DBD yang tersedia saat ini hanya terapi suportif saja. Namun, kini terapi preventif berupa vaksin DBD sedang dikembangkan. Review ini bertujuan untuk mengumpulkan literatur mengenai perkembangan vaksin DBD dan meninjau potensi vaksin DBD berdasarkan studi di berbagai negara.

Kata kunci:Demam Berdarah Dengue, vaksin, perkembangan, potensi

Teks Lengkap:

PDF

Referensi


Avirutnan, P., Fuchs, A., Hauhart, R.E., Somnuke, P., Youn, S., Diamond, M.S., et al. 2010. Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. The Journal of Experimental Medicine, 207 (4), 793–806.

Bhatt, S., Gething, P.W., Brady, O.J., Messina, J.P., Farlow, A.W., Moyes, C.L., et al. 2013. The global distribution and burden of dengue. Nature, 496 (7446), 504–7.

Brady, O.J., Gething, P.W., Bhatt, S., Messina, J.P., Brownstein, J.S., Hoen, A.G., et al. 2012. Refining the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based Consensus. PLOS Neglected Tropical Diseases, 6 (8), e1760.

Capeding, M.R., Tran, N.H., Hadinegoro, S.R.S., Ismail, H.I.H.M., Chotpitayasunondh, T., Chua, M.N., et al. 2014. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. The Lancet, 384 (9951), 1358–65.

Chan, M. and Johansson, M.A. 2012. The Incubation Periods of Dengue Viruses. PLOS ONE, 7 (11), e50972.

Ernawati, Bratajaya, C.N., dan Martina, S.E. 2018. GAMBARAN PRAKTIK PENCEGAHAN DEMAM BERDARAH DENGUE (DBD) DI WILAYAH ENDEMIK DBD. Jurnal Keperawatan, 9, 8.

Guerdan, B.R. 2010. Dengue Fever/Dengue Hemorrhagic Fever. American Journal of Clinical Medicine, 7(2), 51–3.

Guirakhoo, F., Weltzin, R., Chambers, T.J., Zhang, Z.-X., Soike, K., Ratterree, M., et al. 2000. Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus Is Immunogenic and Protective in Nonhuman Primates. Journal of Virology, 74 (12), 5477–85.

Guzman, M.G. and Harris, E., 2015. Dengue. The Lancet, 385 (9966), 453–65.

Hadisoemarto, P.F. and Castro, M.C. 2013. Public Acceptance and Willingness-to-Pay for a Future Dengue Vaccine: A Community-Based Survey in Bandung, Indonesia. PLOS Neglected Tropical Diseases, 7 (9), e2427.

Halstead, S.B. 2008. Dengue virus-mosquito interactions. Annual Review of Entomology, 53, 273–91.

Jonas, W. B. 2005. Mosby’s Dictionary of Complementary and Alternative Medicine. Michigan: Elsevier.

Kementrian Kesehatan RI. 2016a. InfoDATIN DBD 2016. Jakarta: Kementrian Kesehatan RI.

Kementrian Kesehatan RI. 2016b. MENKES: DIBANDING FOGGING, PSN 3M PLUS LEBIH UTAMA CEGAH DBD. Available from: http://www.depkes.go.id/article/print/16021500003/menkes-dibanding-fogging-psn-3m-plus-lebih-utama-cegah-dbd.html [Accessed on 15 Jun 2018].

Khetarpal, N. and Khanna, I. 2016. Dengue Fever: Causes, Complications, and Vaccine Strategies. Journal of Immunology Research, 2016, 1–14.

Lee, B.Y., Bacon, K.M., Cummings, D.A.T., Bailey, R.R., Burke, D.S., Shah, M., et al. 2011. Economic Value of Dengue Vaccine in Thailand. The American Journal of Tropical Medicine and Hygiene, 84 (5), 764–72.

Olivera-Botello, G., Coudeville, L., Fanouillere, K., Guy, B., Chambonneau, L., Noriega, F., et al. 2016. Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2–16 Years in Asia and Latin America. The Journal of Infectious Diseases, 214 (7), 994–1000.

Orellano, P.W., Reynoso, J.I., Stahl, H.-C., and Salomon, O.D. 2016. Cost-utility analysis of dengue vaccination in a country with heterogeneous risk of dengue transmission. Vaccine, 34 (5), 616–621.

Puerta-Guardo, H., Mosso, C., Medina, F., Liprandi, F., Ludert, J.E., and del Angel, R.M. 2010. Antibody-dependent enhancement of dengue virus infection in U937 cells requires cholesterol-rich membrane microdomains. Journal of General Virology, 91 (2), 394–403.

Rajapakse, S., Rodrigo, C., and Rajapakse, A. 2012. Treatment of dengue fever. Infection and Drug Resistance, 103, 103–12.

Raviprakash, K., Defang, G., Burgess, T., and Porter, K. 2009. Advances in dengue vaccine development. Human Vaccines, 5 (8), 520–8.

Sellahewa, K.H. 2013. Pathogenesis of Dengue Haemorrhagic Fever and Its Impact on Case Management. ISRN Infectious Diseases, 2013, 1–6.

Shim, E. 2017. Cost-Effectiveness of Dengue Vaccination Programs in Brazil. The American Journal of Tropical Medicine and Hygiene, 96 (5), 1227–34.

Sridhar, S., Luedtke, A., Langevin, E., Zhu, M., Bonaparte, M., Machabert, T., et al. 2018. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. New England Journal of Medicine, 2018, 1–14.

Tang, K.F. and Ooi, E.E. 2012. Diagnosis of dengue: an update. Expert Review of Anti-infective Therapy, 10 (8), 895–907.

Thongrungkiat, S., Maneekan, P., Wasinpiyamongkol, L., and Prummongkol, S. 2011. Prospective field study of transovarial dengue-virus transmission by two different forms of Aedes aegypti in an urban area of Bangkok, Thailand. Journal of Vector Ecology, 36 (1), 147–52.

Villar, L., Dayan, G.H., Arredondo-García, J.L., Rivera, D.M., Cunha, R., Deseda, C., et al. 2015. Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America. New England Journal of Medicine, 372 (2), 113–123.

Wahala, W.M.P.B. and de Silva, A.M. 2011. The Human Antibody Response to Dengue Virus Infection. Viruses, 3 (12), 2374–95.

WHO. 2009. Dengue: guidelines for diagnosis, treatment, prevention, and control. Geneva: World Health Organization.

WHO. 2011. Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Haemorrhagic Fever. New Delhi: World Health Organization Regional Office for South-East Asia.

WHO. 2017. Updated Questions and Answers related to the dengue vaccine Dengvaxia® and its use. Available from: http://www.who.int/immunization/diseases/dengue/q_and_a_dengue_vaccine_dengvaxia_use/en/ [Accessed on 16 Jun 2018].

WHO. 2018. Meeting of the Strategic Advisory Group of Experts on immunization, April 2018 – conclusions and recommendations. Weekly Epidemiological Record, 93 (23), 329–44.

Zeng, W., Halasa-Rappel, Y.A., Baurin, N., Coudeville, L., and Shepard, D.S. 2018. Cost-effectiveness of dengue vaccination in ten endemic countries. Vaccine, 36 (3), 413–420.




DOI: https://doi.org/10.24198/jf.v16i3.17415

DOI (PDF): https://doi.org/10.24198/jf.v16i3.17415.g8973

Refbacks

  • Saat ini tidak ada refbacks.




Sitasi manajer:   

 

 

Jurnal ini diindeks dalam:

 

 

View My Stats 

ISSN: 1693-1424

e-ISSN: 2716-3075

 

Farmaka by Universitas Padjadjaran is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Copyright © 2013 Jurnal Farmaka - All Right Reserved